



**RNS | 16 August 2022**

## **ImmuPharma plc**

### **Total Voting Rights**

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote. As the Company does not hold any shares in treasury, the total number of voting rights in the Company is also 327,403,115 and this figure of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

**Ends**

**For further information, please contact:**

<b>ImmuPharma PLC</b> ( <a href="http://www.immupharma.com">www.immupharma.com</a> )	+ 44 (0) 207 152 4080
Tim McCarthy, Chief Executive Officer & Chairman	
Lisa Baderoon, Head of Investor Relations & Non-Executive Director	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	
<b>Stanford Capital Partners (Joint Broker)</b>	+44 20 3650 3650
Patrick Claridge, John Howes, Bob Pountney	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	